Article Type
Review
Published
Review
Corrigendum
The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1
Commentary
This commentary is a personal perspective on the approach to COVID-19 vaccination in the United Kingdom.
Original Research
The aim of this study was to observe the safety and efficacy of AZB as an addition to the complex treatment of patients hospitalized with COVID-19. This study is the first exploratory
use of AZB in patients with COVID-19.
Commentary
This article discusses the unprecedented toll of COVID-19 and how it jumpstarted the race towards potential COVID-19 vaccinations, which have been developed in less than a year. It discusses how this feat was accomplished, and how clinical development, manufacturing scale-up and distribution are occurring in parallel for the four COVID-19 vaccine front-runners. It also discusses the many challenges that still lie ahead.